Genocea Biosciences (GNCA) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Genocea Reports Fourth Quarter and Year-End 2015 Financial Results
February 11, 2016 7:30 AM EST- Multiple 2016 clinical milestones for GEN-003 for genital herpes anticipated -- Cancer vaccine strategy targeting generation of first clinical candidate in 2017 -
CAMBRIDGE, Mass., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported corporate highlights and financial results for the fourth quarter and year ended December 31, 2015.
"2015 was another year of important progress for our lead product candidate, GEN-003 for genital herpes, and our ATLASTM T cell target... More
